Login to Your Account

PAHPA Reauthorization Provides Certainty for MCMs

By Mari Serebrov
Washington Editor

Friday, March 15, 2013

The reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA), coupled with the government's intent to purchase a large order of drugs to stockpile against the threat of a radiological/nuclear attack, should make it easier for biotechs developing medical countermeasures (MCMs) to attract investors.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription